Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

16 Oct 2007 07:01

Sopheon PLC16 October 2007 Embargoed Release: 07:00hrs Tuesday 16 October 2007 Sopheon plc ('Sopheon') Beiersdorf Implements Sopheon System in Support of Product Innovation Strategy Accolade(R) Helps Skin Care Market Leader Integrate Management of Global Product Development Process Sopheon, the international software and services company, announced today thatBeiersdorf AG, a leading manufacturer of skin and beauty care products, hasdeployed Sopheon's Accolade product life cycle management (PLM) system tosupport the company's implementation of an enhanced, integrated process fordeveloping and launching new products. The solution is also being used tostrengthen product portfolio decision-making and reporting. Founded in Hamburg, Germany in 1882 by pharmacist Carl Beiersdorf, Beiersdorf'soriginal product patents were for bandages and wound coverings. By the turn ofthe century, the company had expanded into consumer skin care and beautyproducts. Today Beiersdorf is a $7B global producer of regionally brandedconsumer goods with approximately 100 locations and more than 17,000 employees. The company has a reputation for strong customer and product focus, anorientation that has helped, for instance, make NIVEA(R) the best-selling bodycare brand in the world. Cosmetics is a highly competitive, global industry. It is also among thefastest-moving markets in the consumer goods sector. The life of a typicalcosmetic product is only about four years, which means that ongoing, rapidinnovation is a prerequisite to achieving sustained business growth. Beiersdorfis addressing this imperative as a core aspect of its consumer businessstrategy, labeled "Passion for Success." The strategy calls for the company tofocus on fewer but more significant innovations and deliver them to marketfaster. Beiersdorf has long regarded continuous improvement of its new productdevelopment processes as a key factor in maintaining brand superiority. Beiersdorf's adoption of Accolade has allowed the company to advance not onlyits processes for product creation, but its portfolio management capabilities aswell. One principal benefit of the system is that it has given thecross-functional teams engaged in product development across the Beiersdorforganization a common platform through which to access and share project data.The result has been greater transparency and an improved ability to track theprogress of projects in the developmental pipeline. Accolade has also helped toraise the efficiency and accuracy of portfolio reporting and strengthen thecompany's portfolio management and decision-making processes. Sopheon partners Sopheon Vertriebs GmbH and Sopheon Business Applications GmbHwere responsible for the sale, implementation and support of Accolade atBeiersdorf. Dieter Jaeger, chief executive officer of Sopheon Vertriebs GmbH,said, "Beiersdorf has commanded a top position in the international personalcare market for many years, and innovation-led product development has been ahallmark of their success. When we were introduced to Beiersdorf, they alreadyhad in place a standardized, global product development process anchored in bestpractices. With Accolade, we were able to give them a single, user-friendlysoftware system that integrated the management of that process with portfoliomanagement and comprehensive decision-support. Beiersdorf chose Accoladebecause it could match their specific, demanding process requirements. Theyhave subsequently embraced it because it has proven that it helps to ensuresuperior process performance." Accolade(R) is a registered trademark of Sopheon plc. NIVEA(R) is a registered trademark of Beiersdorf AG. All other trademarks and registered trademarks are the sole property of their respective owners. About Beiersdorf AG Founded in Hamburg, Germany in 1882 as a small pharmacy, Beiersdorf has grown tobecome a global company of branded consumer goods with approximately 100affiliates. Since its founding, Beiersdorf has concentrated on skin and beautycare. Beiersdorf is focused on dynamic regions that have above-averagedevelopmental potential, including Asia, South America and Eastern Europe.Beiersdorf is particularly focused on China, Russia, Brazil and India.Beiersdorf products include NIVEA(R), Eucerin(R), Curad(R), Labello(R), 8x4(R),JUVENA(R), la prairie(R), atrix(R) and FUTURO(R). For more information, pleasevisit www.beiersdorf.com. About Sopheon Sopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. Sopheon'ssolutions automate and govern the innovation process, enabling companies toincrease revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com. - Ends - For further information contact: Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735Arif Karimjee, CFOAndrew Tan Hansard Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Nov 202310:15 amRNSForm 8.5 (EPT/NON-RI)
3rd Nov 20238:54 amRNSForm 8.3 - Rivomore Limited - Sopheon plc
2nd Nov 20239:34 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20233:44 pmEQSForm 8.3 - Apex Fundrock Limited : Form 8.3 Apex Fundrock Limited Re: Sopheon PLC
1st Nov 20231:55 pmRNSForm 8.3 - Sopheon plc
1st Nov 202311:23 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202310:51 amGNWForm 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
1st Nov 202310:35 amRNSForm 8.3 - Sopheon PLC
31st Oct 20231:00 pmRNSStatement re Possible Offer
24th Aug 20237:00 amRNSInterim Results
10th Jul 20237:00 amRNSAcquisition
15th Jun 20235:06 pmRNSIssue of Equity
8th Jun 20231:35 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Statement
13th Apr 20234:20 pmRNSIssue of Equity
31st Mar 20239:14 amRNSIssue of Equity
27th Mar 20234:23 pmRNSDirector Shareholdings
24th Mar 20237:00 amRNSDirector Share Purchases
23rd Mar 20237:00 amRNSFinal Results
22nd Feb 20234:59 pmRNSIssue of Equity
6th Feb 20237:00 amRNSDirectorate Change and Notice of Results
30th Jan 20237:00 amRNSTrading Update
20th Sep 202212:01 pmRNSSopheon launches Acclaim Line of SaaS Offerings
2nd Sep 202210:06 amRNSIssue of Equity
1st Sep 20227:00 amRNSNew Release of Award-winning Innovation Product
24th Aug 20227:00 amRNSInterim Results
16th Aug 20227:00 amRNSFive-year, $11.2m Enterprise Agreement
3rd Aug 202210:18 amRNSHolding(s) in Company
21st Jun 202212:20 pmRNSHolding(s) in Company
9th Jun 20222:30 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
6th Jun 20226:02 pmRNSIssue of Equity & TVR
23rd May 20227:00 amRNSDirector Dealing & Issue of Equity
18th May 20227:00 amRNSAcquisition
29th Apr 20225:12 pmRNSHolding(s) in Company
7th Apr 20227:00 amRNSNew Sopheon Software Release
1st Apr 202212:10 pmRNSDirector Shareholdings
24th Mar 20227:00 amRNSFinal Results
25th Jan 20227:00 amRNSTrading Update
17th Jan 20223:15 pmRNSIssue of Equity
20th Dec 20217:00 amRNSAcquisition and Trading Update
24th Sep 20211:52 pmRNSIssue of Equity
16th Sep 202110:00 amRNSHolding(s) in Company
13th Sep 20215:24 pmRNSIssue of Equity
31st Aug 20216:14 pmRNSDirector Shareholdings
25th Aug 20217:00 amRNSInterim Results
13th Jul 20217:00 amRNSNew Release Drives Business Transformation
23rd Jun 20217:00 amRNSSopheon Earns Authority to Operate for NAVSEA
15th Jun 20219:54 amRNSIssue of Equity
10th Jun 202111:43 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.